Peptide index

331 compounds across 19classes. Each one carries an evidence tier, because “there are studies” means something very different for semaglutide than it does for most of this list.

Ctrl K

14 compounds

Abarelix
Approved drug
The first GnRH antagonist approved for advanced prostate cancer — it dropped testosterone in days with no flare, then was pulled from the market because a small percentage of men had immediate systemic allergic reactions.
Oncology, Radiopharmaceutical & Diagnostic
Bortezomib
Approved drug
A dipeptide boronic acid that jams the cell's protein-shredding machinery, which plasma cells depend on more than any other cell type — the drug that rewrote multiple myeloma survival.
Oncology, Radiopharmaceutical & Diagnostic
Carfilzomib
Approved drug
A tetrapeptide epoxyketone that binds the proteasome irreversibly — more potent than bortezomib and far less neurotoxic, at the cost of a real cardiovascular signal.
Oncology, Radiopharmaceutical & Diagnostic
Gallium Ga-68 Dotatate
Approved drug
The PET tracer version of Lutathera — the same somatostatin-seeking peptide carrying an imaging isotope instead of a therapeutic one, used to find neuroendocrine tumours and decide who can be treated.
Oncology, Radiopharmaceutical & Diagnostic
Gallium Ga-68 PSMA-11
Approved drug
A PSMA-targeted PET tracer that finds prostate cancer deposits far smaller than CT or bone scan can see, and decides who is eligible for PSMA radioligand therapy.
Oncology, Radiopharmaceutical & Diagnostic
iRGD
Human trials
A cyclic nine-amino-acid tumour-homing peptide that temporarily opens a transport channel through tumour tissue, letting co-administered chemotherapy actually reach the cancer cells instead of stalling at the stroma.
Oncology, Radiopharmaceutical & Diagnostic
Lutetium Lu-177 Dotatate
Approved drug
A radioactive somatostatin analogue that binds neuroendocrine tumour cells and is dragged inside them, delivering beta radiation from within the tumour rather than through the skin.
Oncology, Radiopharmaceutical & Diagnostic
Lutetium Lu-177 Vipivotide Tetraxetan
Approved drug
A radioactive PSMA-seeking ligand that homes to prostate cancer cells anywhere in the body and irradiates them from the inside — now standard of care in advanced castration-resistant prostate cancer.
Oncology, Radiopharmaceutical & Diagnostic
Melphalan Flufenamide
Human RCT
A lipophilic peptide-drug conjugate that sneaks an alkylating payload into myeloma cells and lets their own aminopeptidases uncap it — approved in the EU, withdrawn in the US after the confirmatory trial showed a survival detriment.
Oncology, Radiopharmaceutical & Diagnostic
Motixafortide
Approved drug
A cyclic 14-residue CXCR4 blocker that releases stem cells from the bone marrow into the blood, letting most myeloma patients collect a full transplant graft in a single apheresis session.
Oncology, Radiopharmaceutical & Diagnostic
Piflufolastat F-18
Approved drug
A fluorine-18 PSMA PET tracer that answers the same question as the gallium tracers but with a two-hour isotope, so doses can be shipped and centres without a generator can run PSMA imaging.
Oncology, Radiopharmaceutical & Diagnostic
Plerixafor
Approved drug
The original CXCR4 blocker — a small-molecule bicyclam, not a peptide — that has been pulling stem cells out of bone marrow for transplant collection since 2008.
Oncology, Radiopharmaceutical & Diagnostic
Romidepsin
Approved drug
A bacterial bicyclic depsipeptide that acts as a prodrug for a zinc-binding HDAC inhibitor, used for cutaneous T-cell lymphoma when skin-directed therapy has failed.
Oncology, Radiopharmaceutical & Diagnostic
Zoptarelin Doxorubicin
Human RCT
A doxorubicin molecule bolted onto an LHRH peptide so that only LHRH-receptor-positive tumours take it up — a beautiful targeting idea that failed outright in phase 3.
Oncology, Radiopharmaceutical & Diagnostic